home / stock / gild / gild articles

GILD Articles, Gilead Sciences Inc. - From 03/07/24

Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley | Benzinga

Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy | Benzinga

Gilead Sciences Inc (NASDAQ:GILD) and Merck & Co Inc (NYSE:MRK) released results from the Phase 2 clinical study evaluating the ...

Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers | Benzinga

Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...

Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges | Benzinga

The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including ...
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return...

Why Is Gilead Sciences Stock Trading Lower Today? | Benzinga

Gilead Sciences Inc (NASDAQ:GILD) said it paused tumor study enrollment. The Food and Drug Administration (FDA) subsequently requested a partial...

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields | Benzinga

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have hig...
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst | Benzinga

Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire  CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...

Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B | Benzinga

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 ...

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics | Benzinga

Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in Q1 of 2024. Un...
Previous 10 Next 10